// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Long-term risk of cardiovascular disease following fertility therapy: systematic review and meta-analysis

N. Dayan - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Symptoms and Health Perception in Atrial Fibrillation Patients from the Swiss Atrial Fibrillation Cohort Study (Swiss-AF)

P. Ammann - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Influence of peri-operative stroke on 5-year mortality following open heart surgery

J. Higgins - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

N-terminal pro-B-type natriuretic peptide (NT-proBNP) is associated with stroke among hospitalized medical patients: an APEX trial substudy

G. Chi - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

betrixaban

Evaluating compliance of labelling on tobacco packets with WHO recommendations and national legislation in 12 middle eastern countries across levels of economic development

H. Mir - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

North American compliance with the shock reduction programming recommendations

M. Bennett - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Aortic regurgitation and haemodynamic performance of a third-generation balloon-expandable transcatheter heart valve. Results from the SOURCE 3 registry echocardiographic substudy at 1 year

S. Fernandez - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Surgical ablation of atrial fibrillation evaluation (SAFE): a cost analysis

G.R. McClure - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Differences in two-year outcomes according to type of atrial fibrillation: results from the GARFIELD-AF registry

G. Kayani - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Risk for adverse outcome events according to paroxysmal vs. non-paroxysmal atrial fibrillation

C. Sticherling - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

The impact of renal disease on target vessel revascularisation following percutaneous coronary intervention: a contemporary analysis of 45,287 patients from the British Columbia Cardiac Registry

A. Levin - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

N/A

Long-term follow-up of patients with non-obstructive coronary artery disease presenting with stable angina

C.K. Kissel - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Electrocardiograms in low-risk patients undergoing an annual health examination

L. Wilson - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

In vivo near-infrared fluorescence (NIRF) molecular imaging of atherosclerosis

P. Lavoie-L'allier - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

ICAM-1

Post-hoc analysis of Confidence II, Protect I, Shake the habit I and Shake the habit II studies in mild to moderate hypertensive patients treated with perindopril and atorvastatin concomitantly

J.S. Sampalis - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

atorvastatin + Perindopril

Ideal cardiovascular health and aortic valve stenosis incidence in apparently healthy men and women

B. Arsenault - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Do atrial fibrillation patients with history of cerebrovascular accidents receive guideline-concordant stroke preventive therapies? Insights from the prospective SPRINT-AF registry

E. Lockwood - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Relationship of outpatient provider volume and lipid screening performance measure adherence among patients at risk of cardiovascular disease

J.A. Udell - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

The effects of two exercise therapy methods on cardio-metabolic risk factors in diabetic overweight middle-aged females

M. Kaviani - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

ILS-969

Do atrial fibrillation detection rates differ based on presenting symptomatology in patients at risk of atrial fibrillation and stroke? Results from the REVEAL AF study

J.A. Reiffel - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved